Eckardt L, Häusler K G, Ravens U, Borggrefe M, Kirchhof P
Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Münster, Deutschland.
Klinik und Poliklinik für Neurologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.
Herz. 2016 Dec;41(8):677-683. doi: 10.1007/s00059-016-4503-8.
The first European Society of Cardiology (ESC) guidelines on atrial fibrillation (AF) developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) were published in August 2016. These guidelines replace the revised guidelines from 2012 and contain some interesting new aspects. The topics range from the pathophysiology through diagnostics, therapy and stroke prevention up to special clinical situations, such as atrial fibrillation in cardiopathy, sport and pregnancy. Early screening, patient informed consent, individualized therapy and the modification of factors promoting atrial fibrillation are of particular importance. The guidelines recommend the establishment of AF heart teams, containing specialists from various disciplines. The guidelines also underline the importance of non-vitamin K‑dependent oral anticoagulants (NOAC) for stroke prevention compared to standard anticoagulants with vitamin K antagonists. For symptomatic and especially paroxysmal atrial fibrillation, the guidelines emphasize the importance of an antiarrhythmic treatment with catheter ablation and/or pharmaceutical antiarrhythmic therapy in addition to a frequency regulating therapy.
欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的首份心房颤动（AF）指南于2016年8月发布。这些指南取代了2012年的修订版指南，并包含一些有趣的新内容。主题涵盖从病理生理学到诊断、治疗和中风预防，直至特殊临床情况，如心脏病、运动和妊娠中的心房颤动。早期筛查、患者知情同意、个体化治疗以及促进心房颤动的因素的修正尤为重要。指南建议组建房颤心脏团队，其中包括来自各个学科的专家。指南还强调，与使用维生素K拮抗剂的标准抗凝剂相比，非维生素K依赖口服抗凝剂（NOAC）在预防中风方面的重要性。对于有症状尤其是阵发性心房颤动，指南强调除频率调节治疗外，采用导管消融和/或药物抗心律失常治疗进行抗心律失常治疗的重要性。
